Terminated × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
6 enrolled
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase 3 Terminated
102 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase 1/2 Terminated
28 enrolled
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
CANOPY-1
Phase 3 Terminated
673 enrolled 38 charts
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase 1/2 Terminated
25 enrolled 11 charts
PRIMING
Phase 1 Terminated
2 enrolled 10 charts
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
C-TIL051 in Non-Small Cell Lung Cancer
Phase 1 Terminated
1 enrolled
HBI-8000
Phase 2 Terminated
5 enrolled 8 charts
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Phase 1/2 Terminated
36 enrolled
KEYNOTE-867
Phase 3 Terminated
448 enrolled 24 charts
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Phase 3 Terminated
162 enrolled
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Phase 1/2 Terminated
26 enrolled 13 charts
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2 Terminated
6 enrolled 7 charts
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Phase 2 Terminated
106 enrolled 21 charts
SABRseq
Phase 1 Terminated
13 enrolled 14 charts
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
243 enrolled 21 charts
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Phase 2 Terminated
21 enrolled
IRRADIATE-Lung
Phase 2 Terminated
19 enrolled 11 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
Lotus
Phase 3 Terminated
25 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
KEYNOTE B36
Phase 2 Terminated
15 enrolled
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Phase 2 Terminated
9 enrolled 15 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
STARLING
Phase 1 Terminated
31 enrolled
Acclaim-2
Phase 1/2 Terminated
5 enrolled
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Phase 1 Terminated
47 enrolled
V941-001
Phase 1 Terminated
70 enrolled 18 charts
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Phase 2 Terminated
5 enrolled
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
Phase 2 Terminated
11 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Phase 1 Terminated
8 enrolled 11 charts
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
Phase 2 Terminated
76 enrolled 17 charts
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Phase 2 Terminated
19 enrolled 16 charts
CANOPY-N
Phase 2 Terminated
88 enrolled 21 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
IMM60 and Pembrolizumab in Melanoma and NSCLC
Phase 1/2 Terminated
1 enrolled
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
6 enrolled 14 charts
PIL
Phase 1/2 Terminated
4 enrolled 5 charts
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Phase 1/2 Terminated
34 enrolled 16 charts
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
TORCH
Phase 1 Terminated
10 enrolled
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
Phase 2 Terminated
23 enrolled 12 charts